HIV vaccine: hopes and hurdles

The AIDS vaccine development effort has already been facing various scientific and economic challenges. The fundamental challenge resides at the level of understanding the basic biology of HIV-1 infection and an effective antiviral immune response. There is a need to design immunogens that can elici...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2011-11, Vol.16 (21), p.948-956
Main Authors: Chhatbar, Chintan, Mishra, Ritu, Kumar, Ashish, Singh, Sunit Kumar
Format: Article
Language:English
Subjects:
AIDS Vaccines - immunology
AIDS Vaccines - metabolism
AIDS Vaccines - therapeutic use
Biological and medical sciences
Drug Discovery
General pharmacology
HIV Antibodies - immunology
HIV Antibodies - physiology
HIV Infections - immunology
HIV Infections - prevention & control
HIV-1 - immunology
HIV-1 - physiology
Humans
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The AIDS vaccine development effort has already been facing various scientific and economic challenges. The fundamental challenge resides at the level of understanding the basic biology of HIV-1 infection and an effective antiviral immune response. There is a need to design immunogens that can elicit cross-clade neutralizing antibodies (NAbs) along with effective T-cell responses against a wide variety of primary HIV isolates. We must exploit the capabilities of the vaccine-elicited cytotoxic T cells and the NAb responses in controlling HIV-1 replication. A coordinated approach is required to understand the intricacies involved in the basic immune responses against HIV infection as well as the cross-clade effectiveness of an AIDS vaccine.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2011.08.013